Development of orphan drugs for rare diseases

• Published in: Clinical and experimental pediatrics Vol. 67; no. 7; pp. 315 - 327
• Main Author: Yoo, Han-Wook
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Pediatric Society 01.07.2024; The Korean Pediatric Society; 대한소아청소년과학회
• Subjects: clinical trial; drug development; genetic disorders; orphan diseases; orphan drug; rare disease; Review; strategy; 소아과학; Genetic disorders; Orphan diseases; Rare disease; Clinical trial; Strategy; Drug development; Orphan drug
• ISSN: 2713-4148; 2713-4148
• DOI: 10.3345/cep.2023.00535

Most rare diseases (orphan diseases) still lack approved treatment options despite major advances in research providing the necessary tools to understand their molecular basis and legislation providing regulatory and economic incentives to expedite the development of specific therapies. Addressing this translational gap is a multifaceted challenge, a key aspect of which is the selection of an optimal therapeutic modality to translate advances in rare disease knowledge to potential medicines known as orphan drugs. There are several strategies for developing orphan drugs for rare genetic disorders, including protein replacement therapies, small-molecule therapies (e.g., substrate reduction, chemical chaperone, cofactor, expression modification, and read-through therapies), monoclonal antibodies, antisense oligonucleotides, small interfering RNA or exon skipping therapies, gene replacement and direct genome-editing therapies, mRNA therapy, cell therapy, and drug repurposing. Each strategy has its own strengths and limitations in orphan drug development. Furthermore, numerous hurdles are present in clinical trials of rare genetic diseases because of difficulty with patient recruitment, unknown molecular physiology, the natural history of the disease, ethical concerns regarding pediatric patients, and regulatory challenges. To address these barriers, the rare genetic diseases community, including academic institutions, industry, patient advocacy groups, foundations, payers, and government regulatory and research organizations, must become engaged in discussions about these issues.